. Author manuscript; available in PMC: 2010 Jul 27.

Published in final edited form as: Neuropsychobiology. 2008 Oct 3;58(2):81–90. doi: 10.1159/000159776

Table 5.

Urinary free- and conjugated-naltrexone levels after 2.22 mg/kg intravenous bolus administration of naltrexone hydrochloride in Wistar, LAD-1 and HAD-1 rats

Groups	Time, h	Free naltrexone		Conjugated naltrexone		Total cumulative naltrexone, % (significant)
Groups	Time, h	excretion, μg	cumulative, % (significant)	excretion, μg	cumulative, % (not significant)	Total cumulative naltrexone, % (significant)
Wistar	12	13.80±0.56	2.09	4.66±3.15	0.71	2.80±0.77
	24	0±0	2.09	1.13±0.75	0.88	2.97±0.73
	48	0±0	2.09	1.08±0.51	1.05	3.14±0.79
LAD-1	12	12.42±0.25	2.75	8.69±3.82	1.93	4.68±2.01
	24	0.27±0.34	2.81	0.04±0.09	1.94	4.75±2.04
	48	0.26±0.46	2.87	0±0	1.94	4.81±1.97
HAD-1	12	19.46±0.51	4.06	7.67±5.17	1.48	5.53±1.21
	24	0±0	4.06	1.68±1.06	1.60	5.66±1.16
	48	0.24±0.54	4.34	0.73±0.91	1.46	5.80±1.22

Total cumulative % naltrexone excreted is significant with HAD-1 > Wistar, but no significant differences between Wistar and LAD-1 rats and also between HAD-1 and LAD-1 at 5% level of significance.

Free cumulative % naltrexone excreted is significant with HAD-1 > Wistar, but no significant difference between Wistar and LAD-1 rats and also between HAD-1 and LAD-1 at 5% level of significance.

Total cumulative % conjugated naltrexone excreted is not significant (i.e. no significant difference between Wistar, LAD-1 and HAD-1 rats at 5% level of significance).